| Aug 2 |
MiMedx Group Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 1 |
MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
|
| Jul 31 |
MiMedx: Q2 Earnings Snapshot
|
| Jul 31 |
MiMedx Group Non-GAAP EPS of $0.08 in-line, revenue of $87.21M misses by $1.71M
|
| Jul 31 |
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
|
| Jul 31 |
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
|
| Jul 22 |
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
|
| Jul 2 |
Cantor starts MiMedx at overweight, cites valuation, product offerings
|
| Jul 1 |
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
|
| Jun 24 |
With 45% ownership, MiMedx Group, Inc. (NASDAQ:MDXG) has piqued the interest of institutional investors
|
